VCNX on OTC

VACCINEX, INC.

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PMGC Holdings Inc., Ernexa Therapeutics Inc. or NovaBridge Biosciences, or pick any stock.

  • TickerVCNX on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRochester, New York1
  • Incorporated inDE2
  • Business address1895 Mount Hope Ave, Rochester, Ny 146202
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for neurodegenerative diseases, cancer, and autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the activity of immune and inflammatory cells at sites of injury, cancer, or infection. We have used our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of Alzheimer’s di…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-3117.3%Operating margin4
-3100.5%Net margin4
5.4%Revenue growth, 20244
-$16.2MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$12.5M
  • Interest0¢$2.0K

Out of $601.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$601.0K in 2024−17% since 2018
0$250.0K$500.0K$750.0K$1.0M2018: $724.0K$724.0K20182019: $523.0K$523.0K2019−28%2020: $625.0K$625.0K2020+20%2021: $900.0K$900.0K2021+44%2022: $275.0K$275.0K2022−69%2023: $570.0K$570.0K2023+107%2024: $601.0K$601.0K2024+5%
Operating income567894-$18.7M in 2024−31% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$27.3M-$27.3M20182019: -$32.0M-$32.0M2019+17%2020: -$28.3M-$28.3M2020−12%2021: -$22.5M-$22.5M2021−21%2022: -$19.9M-$19.9M2022−11%2023: -$22.9M-$22.9M2023+15%2024: -$18.7M-$18.7M2024−18%
Net income56794-$18.6M in 2024−37% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$29.5M-$29.5M20182019: -$31.9M-$31.9M2019+8%2020: -$28.9M-$28.9M2020−9%2021: -$22.4M-$22.4M2021−22%2022: -$19.8M-$19.8M2022−11%2023: -$20.3M-$20.3M2023+2%2024: -$18.6M-$18.6M2024−8%
Fiscal year2018201920202021202220232024
Revenue$724.0K5$523.0K6$625.0K7$900.0K8$275.0K9$570.0K4$601.0K4
Cost of revenue$1.0M5$199.0K6$2.0K7
Research and development$22.4M5$25.7M6$21.5M7$17.2M8$14.0M9$16.6M4$12.5M4
Operating expenses$23.4M8$20.2M9$23.5M4$19.3M4
Operating income-$27.3M5-$32.0M6-$28.3M7-$22.5M8-$19.9M9-$22.9M4-$18.7M4
Interest$392.0K5$489.0K7$809.0K8$2.0K9$1.0K4$2.0K4
Income before tax-$22.4M8-$19.8M9-$20.3M4-$18.6M4
Income tax$05$06$07$08$09$04$04
Net income-$29.5M5-$31.9M6-$28.9M7-$22.4M7-$19.8M9-$20.3M4-$18.6M4
Earnings per share-$0.788-$98.059-$43.684-$8.884
Earnings per share (diluted)-$0.788-$98.059-$43.684-$8.884
Shares (weighted, basic)28.8M shares8202.1K shares9463.7K shares42.1M shares4
Shares (weighted, diluted)28.8M shares8202.1K shares9463.7K shares42.1M shares4

Compare VACCINEX, INC. with another company

Leadership

Who has led VACCINEX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Maurice Zauderer2018–2024

President

  1. Maurice Zauderer2018–2024

Chief financial officer

  1. Scott E. Royer2018–2023
  2. Jill Sanchez2024

Chief operating officer

  1. Raymond E. Watkins2018–2020
20202025
Board members and other officers (12)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerElizabeth S. Evans named Apr 12, 2024 to Sep 27, 202428
  • Executive OfficerErnest S. Smith Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • Director, Executive OfficerMaurice S. Zauderer, Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • DirectorBala S. Manian Ph.D. named Apr 12, 2024 to Sep 27, 202428
  • DirectorGerald E. Van Strydonck named Apr 12, 2024 to Sep 27, 202428

Former names

  • VACCINEX INCNov 12, 2002 to May 9, 20052

Timeline

  1. Aug 9, 2018New chief executive Maurice Zauderer becomes CEO13

Filings

266 filings to the SEC since October 2021: 5 annual reports, 10 quarterly reports, 50 major events, 74 insider forms, 21 large holders, 4 private raises, 102 other. The latest 20:

  1. Apr 15, 202510-K EDGAR
  2. Apr 1, 2025NT 10-K EDGAR
  3. Mar 27, 202515-12G EDGAR
  4. Mar 25, 2025EFFECT EDGAR
  5. Mar 25, 2025EFFECT EDGAR
  6. Mar 25, 2025EFFECT EDGAR
  7. Mar 25, 2025EFFECT EDGAR
  8. Mar 25, 2025EFFECT EDGAR
  9. Mar 25, 2025EFFECT EDGAR
  10. Mar 25, 2025EFFECT EDGAR
  11. Mar 25, 2025EFFECT EDGAR
  12. Mar 25, 2025EFFECT EDGAR
  13. Mar 25, 2025EFFECT EDGAR
  14. Mar 25, 2025EFFECT EDGAR
  15. Mar 25, 2025EFFECT EDGAR
  16. Mar 25, 2025EFFECT EDGAR
  17. Mar 25, 2025EFFECT EDGAR
  18. Mar 25, 2025EFFECT EDGAR
  19. Mar 25, 2025POS AM EDGAR
  20. Mar 25, 2025POS AM EDGAR

The 266 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 15 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 9, 2024FRIEDBERG ALBERTDirectorBuy100$4.51$451Form 4
Aug 6, 2024FCMI Parent Co.10% ownerBuy2,753$4.92$13.5KForm 4
Aug 5, 2024FCMI Parent Co.10% ownerBuy3,653$4.60$16.8KForm 4
Aug 1, 2024FRIEDBERG ALBERTDirectorBuy11,703$4.72$55.2KForm 4
Jul 31, 2024FCMI Parent Co.10% ownerBuy200,000$6.15$1.2MForm 4
May 30, 2024FRIEDBERG ALBERTDirectorBuy861$5.20$4.5KForm 4
May 29, 2024FRIEDBERG ALBERTDirectorBuy957$4.95$4.7KForm 4
Apr 19, 2024FRIEDBERG ALBERTDirectorBuy282$4.73$1.3KForm 4
Dec 26, 2023Van Strydonck, Gerald E.DirectorSale3,149$0.72$2.3KForm 4
Dec 8, 2023Van Strydonck, Gerald E.DirectorSale1,334$0.67$894Form 4
Oct 4, 2023Zauderer MauricePresident and CEOBuy5,000$0.97$4.8KForm 4
Oct 3, 2023Zauderer MauricePresident and CEOBuy505,000$1.00$504.6KForm 4
Oct 3, 2023FRIEDBERG ALBERTDirectorBuy3,000,000$1.00$3.0MForm 4
Feb 23, 2022Van Strydonck, Gerald E.DirectorBuy20,000$1.32$26.4KForm 4
Jan 27, 2022Frieberg Jacob B.DirectorBuy90,090$1.11$100.0KForm 4
Jan 27, 2022FRIEDBERG ALBERTDirectorBuy3,603,602$1.11$4.0MForm 4
Jan 27, 2022Zauderer MauricePresident and CEOBuy1,801,801$1.11$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 18, 2024Raised $200,155 in a private offering of securities Form D: $9.2 million offered in all Form D
  2. Mar 29, 2024Raised $1.8 million in a private offering of equity Form D: $3.5 million offered in all Form D
  3. Mar 28, 2024Filed a private offering of securities Form D: $1.5 million offered in all Form D
  4. Mar 28, 2024Raised $1.2 million in a private offering of equity Form D: $2.5 million offered in all Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33